Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to significant operational issues and a drastic reduction in earnings guidance following the announcement of delays in the launch of its new sleep apnea device, Inspire V [2][4]. Company Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V was delayed due to multiple issues, including inadequate training and onboarding of treatment centers, software update delays, and excess inventory leading to poor demand [2]. - The company reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share to a new range of $0.40 to $0.50 per share [2]. Stock Market Reaction - Following the announcement on August 5, 2025, Inspire's stock price dropped by $42.04, or 32.4%, closing at $87.91 per share, resulting in significant losses for investors [3]. Legal Allegations - The class action complaint alleges that during the class period, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [4]. - Specific allegations include poor demand for Inspire V due to surplus inventory, incomplete training for treatment centers, and failure to ensure necessary IT systems and Medicare reimbursement were in place at launch [4].

Core Viewpoint - The lawsuit against DeFi Technologies alleges that the company made misleading statements regarding its financial performance and competitive landscape, leading to significant losses for investors during the specified class period [2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased securities from May 12, 2025, to November 14, 2025, alleging false statements and omissions regarding the company's DeFi arbitrage strategy and competition [2]. - Key allegations include delays in executing the DeFi arbitrage strategy, understatement of competition from digital asset treasury companies, and an inability to meet previously issued revenue guidance for fiscal year 2025 [2]. Group 2: Financial Impact - On November 6, 2025, DeFi's share price fell by approximately 7.43%, from $1.75 to $1.62, following a press release indicating that digital asset treasury companies had absorbed a significant share of arbitrage opportunities [3]. - Following the Q3 2025 financial results announcement on November 14, 2025, which reported a nearly 20% revenue decline and a lowered revenue forecast from $218.6 million to approximately $116.6 million, the share price dropped by about 14.63%, from $1.23 to $1.05 [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Integer Holdings Corporation (NYSE: ITGR) for the period between July 25, 2024, and October 22, 2025, due to alleged misleading statements regarding the company's competitive position and sales performance in the electrophysiology market [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Integer Holdings Corporation overstated its competitive position in the electrophysiology manufacturing market and mischaracterized its EP devices as long-term growth drivers for its cardio and vascular segment [5]. - It is alleged that Integer experienced a deterioration in sales related to two of its EP devices, contradicting its claims of strong visibility into customer demand [5]. - The lawsuit asserts that the positive statements made by the defendants about Integer's business and prospects were materially false and misleading, leading to investor damages when the true details became public [5]. Group 2: Participation Information - Investors who purchased Integer common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must file a motion with the court by February 9, 2026, to represent other class members in the litigation [1][3].

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into possible securities fraud involving Instacart, potentially leading to a class action lawsuit on behalf of investors [1][3]. Company Summary - Instacart's stock experienced a decline on December 10, 2025, following a report that accused the company of charging different prices for the same items, which could undermine customer trust [3]. - The report was conducted by Consumer Reports, Groundwork Collaborative, and More Perfect Union, highlighting significant concerns regarding pricing practices [3]. Legal Actions - Investors are encouraged to contact the Portnoy Law Firm to discuss their legal rights and options for pursuing claims to recover losses [2][4]. - The Portnoy Law Firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in StubHub Holdings, Inc. ("StubHub Holdings, Inc." or the "Company") (NYSE: STUB) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of StubHub Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired StubHub common stock pursuant and/or traceable to the registra ...

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Primo Brands Corporation / Primo Water Corporation ("Primo Brands Corporation / Primo Water Corporation" or the "Company") (NYSE: PRMB) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Primo Brands Corporation / Primo Water Corporation investors who were adversely affected by alleged securities fraud between June 17, 2024 and November 6, 2025. Follow the link below ...

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: ht ...

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Blue Owl Capital Inc. ("Blue Owl Capital Inc." or the "Company") (NYSE: OWL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Blue Owl Capital Inc. investors who were adversely affected by alleged securities fraud between February 6, 2025 and November 16, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/ps ...

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. for alleged securities fraud affecting investors between January 8, 2024, and September 17, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without FDA approval [2] - These design changes allegedly rendered the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [2] - The enhancements claimed for the G7, including its reliability, accuracy, and functionality, were reportedly overstated by the defendants [2] - The true scope and severity of the issues and health risks associated with the G7 devices were allegedly downplayed by the defendants [2] - The situation has subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [2] - Public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [2] Group 2: Legal Process and Participation - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Stride, Inc. ("Stride" or the "Company") (NYSE: LRN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Stride investors who were adversely affected by alleged securities fraud between October 22, 2024 and October 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/stride-inc-lawsuit-submission-form ...